Patients with inflammatory conditions and concomitant cirrhosis who are treated with tumor necrosis factor inhibitors face heightened risk of serious infections and other complications, according to new Cleveland Clinic research.
Study reveals that the successful downstaging of advanced HCC via locoregional therapy prior to transplant yields 5-year survival rate of 60 percent. Two liver experts explain the impact on patients and the transplant community.
HALT-HCC is practical, easy to implement and outperformed other selection criteria. It has the potential to become a new clinical tool that can lead to more efficient use of donated organs.
Denied surgery elsewhere, a 77-year-old undergoes a complex liver resection for hepatocellular carcinoma with outstanding results.